<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01541865</url>
  </required_header>
  <id_info>
    <org_study_id>CR002-020</org_study_id>
    <nct_id>NCT01541865</nct_id>
  </id_info>
  <brief_title>Treatment of Resistant Hypertension Using a Radiofrequency Percutaneous Transluminal Angioplasty Catheter</brief_title>
  <acronym>REDUCE-HTN</acronym>
  <official_title>Treatment of Resistant Hypertension Using a Radiofrequency Percutaneous Transluminal Angioplasty Catheter (REDUCE-HTN) - POST MARKET APPROVAL CLINICAL SURVEILLANCE STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Study objective is to assess the performance of the Vessix V2 Renal Denervation System
      for the treatment of uncontrolled hypertension using an innovative percutaneous Radio
      Frequency (RF) balloon catheter renal denervation device.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the hypothesis that the Vessix V2 Renal Denervation System can be
      employed to reduce systolic and diastolic blood pressure at 6 months as compared to
      pre-treatment baseline blood pressures.

      Patient blood pressure will be measured by in the office according to recognized
      international techniques and standards.

      Procedural success shall be defined as ability to complete the renal denervation treatment
      using the V2 balloon catheter device and RF generator.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Systolic and Diastolic Blood Pressure at Six (6) Months as Measured by Office-based Blood Pressure Assessment</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Change in systolic and diastolic blood pressure at six (6) months as measured by office-based blood pressure assessment following therapeutic renal denervation compared to baseline. Office blood pressure will be measured using a validated electronic device according to a standardized procedure. .</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Systolic and Diastolic Blood Pressure at Six (6) Months as Measured by 24-hour Ambulatory Blood Pressure</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Change in systolic and diastolic blood pressure at six (6) months as measured by 24-hour ambulatory blood pressure monitoring (ABPM) following therapeutic renal denervation compared to baseline using a validated ABPM device.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absence of Flow Limiting Stenosis in the Renal Artery</measure>
    <time_frame>6 months</time_frame>
    <description>Absence of flow limiting stenosis in the renal artery at six (6) months follow up time point as measured by renal duplex ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Artery Dissection or Perforation During the Procedure That Requires Stenting or Surgery</measure>
    <time_frame>Duration of the procedure (average of 65 minutes)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Artery Infarction or Embolus</measure>
    <time_frame>Duration of the procedure (average of 65 minutes)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrovascular Accident (CVA) at Time of Procedure</measure>
    <time_frame>Duration of the procedure (average of 65 minutes)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction at Time of Procedure</measure>
    <time_frame>Duration of the procedure (average of 65 minutes)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sudden Cardiac Death at Time of Procedure</measure>
    <time_frame>Duration of the procedure (average of 65 minutes)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographically-documented Renal Stenosis Requiring an Intervention</measure>
    <time_frame>2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Symptomatic Orthostatic Hypotension</measure>
    <time_frame>2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypertensive Emergency Necessitating Hospital Admission (Unrelated to Medication and/or Non-compliance)</measure>
    <time_frame>2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in Estimated Glomerular Filtration Rate (eGFR) &gt;25%</measure>
    <time_frame>2 Years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">146</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Renal Denvervation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All subjects who meet the inclusion criteria and are enrolled in this trial will be treated with the Vessix Renal Denervation System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Renal Denervation</intervention_name>
    <description>percutaneous renal denervation using the Vessix RF balloon catheter</description>
    <arm_group_label>Renal Denvervation</arm_group_label>
    <other_name>Vessix V2 Renal Denervation System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects who have provided written informed consent;

          2. Subjects who are ≥ 18 years and ≤ 75 years of age;

          3. Subjects who have Systolic Blood Pressure (SBP) ≥ 160 mm Hg based on an average of
             three (3) office-based blood pressure readings (seated) measured according to
             protocol;

          4. Subjects with ≥ 3 anti-hypertensive drugs at maximally tolerated doses with stable
             regimen for at least 2 weeks prior to enrollment

          5. Subjects with a estimated glomerular filtration rate (eGFR) ≥ 45 ml/min/1.73m^2;

          6. Suitable renal artery anatomy

          7. Subjects who are willing and able to comply with all study procedures.

        Exclusion Criteria:

          1. Subjects with known/diagnosed secondary hypertension;

          2. Subjects who are contraindicated for anticoagulation medications (heparin, aspirin,
             Angiomax, etc.), analgesic medications (morphine, fentanyl, etc.), anxiolytic
             medications (alprazolam, lorazepam, diazepam, etc.) or other medications required for
             an interventional procedure;

          3. Subjects with known bleeding or hyper-coagulation disorders;

          4. Subjects who have type 1 diabetes mellitus;

          5. Subjects who have experienced a myocardial infarction, unstable angina pectoris,
             uncompensated heart failure, or a cerebrovascular accident within six (6) months prior
             to the screening visit, or have widespread atherosclerosis, with documented
             intravascular thrombosis or unstable plaques;

          6. Subjects who have planned percutaneous vascular or surgical intervention for any
             reason within the next 6 months;

          7. Subjects who have hemodynamically significant valvular heart disease for which
             reduction of blood pressure would be considered hazardous;

          8. Subjects who have an implantable cardioverter defibrillator, pacemaker, or clinically
             significant abnormal electrocardiogram

          9. Subjects who have any serious medical condition, which in the opinion of the
             investigator, may adversely affect patient safety or the efficacy of the procedure in
             the study (i.e., patients with clinically significant peripheral vascular disease,
             abdominal aortic aneurysm, bleeding disorders such as thrombocytopenia, hemophilia, or
             significant anemia);

         10. Subjects who are pregnant, nursing or planning to become pregnant;

         11. Subjects who have a known, unresolved history of drug use or alcohol abuse/dependency;

         12. Subjects who are currently enrolled in any investigational study wherein patient
             participation has not been completed;

         13. Subjects who, for any reason, may not be able to understand or comply with
             instructions;

         14. Subjects who are contraindicated for intravascular contrast material;

         15. Subjects who are currently taking estrogen or any estrogen-like compound.

         16. Subjects who have had a prior renal denervation procedure

         17. Subjects with prior intervention to right or left renal artery;

         18. Subjects with ≥ 30% renal artery stenosis

         19. Subjects with severe femoral, renal, iliac or aortic calcification that may cause a
             potential complication at the time of the procedure;

         20. Subjects in which the physician is unable to safely cannulate the renal artery;

         21. Subjects in which the physician is unable to percutaneously access the femoral artery;

         22. Subjects with one kidney.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Horst Sievert, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CardioVascular Center Frankfurt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Prince Charles Hospital, Cardiology Clinical Research Centre</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Cardiovascular Research Centre (Monash Heart)</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH Linz</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salzburger Landeskliniken Universitats Krankenhaus</name>
      <address>
        <city>Salzburg</city>
        <zip>A-5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OLV Ziekenhuis</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universiaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>F-31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentralklinik Bad Berka GmbH</name>
      <address>
        <city>Bad Berka</city>
        <zip>99437</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kardiologische Praxis Main-Taunus</name>
      <address>
        <city>Bad Soden/Taunus</city>
        <zip>65812</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vascular Center Berlin, Ev. Königin Elisabeth Hospital</name>
      <address>
        <city>Berlin</city>
        <zip>10365</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincenz Krankenhaus Abt. Kardiologie</name>
      <address>
        <city>Essen</city>
        <zip>45141</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CardioVascular Center, Sankt Katharinen Krakenhaus</name>
      <address>
        <city>Frankfurt</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamburg University Cardiovascular Center</name>
      <address>
        <city>Hamburg</city>
        <zip>22527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saarland University Hospital Department of Internal Medicine III Non-surgical Intensive Care, Cardiology and Angiology</name>
      <address>
        <city>Homburg/Saar</city>
        <zip>D-66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>German Heart Center Munich</name>
      <address>
        <city>Münich</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center-Thorax Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Grafton</city>
        <state>Auckland</state>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Angiography Unit Ltd</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Geneva, Cardiology Center</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Switzerland University Hospital Clinic for Cardiology</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Sievert H, Schofer J, Ormiston J, Hoppe UC, Meredith IT, Walters DL, Azizi M, Diaz-Cartelle J, Cohen-Mazor M. Renal denervation with a percutaneous bipolar radiofrequency balloon catheter in patients with resistant hypertension: 6-month results from the REDUCE-HTN clinical study. EuroIntervention. 2015 Feb;10(10):1213-20. doi: 10.4244/EIJY14M12_01.</citation>
    <PMID>25452197</PMID>
  </results_reference>
  <results_reference>
    <citation>Persu A, Sapoval M, Azizi M, Monge M, Danse E, Hammer F, Renkin J. Renal artery stenosis following renal denervation: a matter of concern. J Hypertens. 2014 Oct;32(10):2101-5. doi: 10.1097/HJH.0000000000000323.</citation>
    <PMID>25186534</PMID>
  </results_reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2012</study_first_submitted>
  <study_first_submitted_qc>February 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2012</study_first_posted>
  <results_first_submitted>September 15, 2015</results_first_submitted>
  <results_first_submitted_qc>September 15, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 16, 2015</results_first_posted>
  <last_update_submitted>October 23, 2015</last_update_submitted>
  <last_update_submitted_qc>October 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypertension, renal denervation, uncontrolled hypertension, medication resistant hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment of up to 150 subjects was planned; 146 subjects were enrolled at 23 centers in the Europe, Australia and New Zealand from February 22, 2012 to April 8, 2013.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Renal Denervation</title>
          <description>All subjects who meet the inclusion criteria and are enrolled in this trial will be treated with the Vessix Renal Denervation System.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="146"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Renal Denervation</title>
          <description>All subjects who meet the inclusion criteria and are enrolled in this trial will be treated with the Vessix Renal Denervation System.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="146"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.1" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black, Asian, Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type 2 Diabetes</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Type 2 Diabetes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Diabetic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Coronary Artery Disease</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Coronary Artery Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Coronary Artery Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Congestive Heart Failure</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Congestive Heart Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Congestive Heart Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Dyslipidemia</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Dyslipidemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Dyslipidemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Systolic Blood Pressure</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="182.4" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Diastolic Blood Pressure</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100.2" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Heart Rate</title>
          <units>beats/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.7" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estimated glomerular filtration rate (eGFR)</title>
          <units>mL/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82.7" spread="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Creatinine</title>
          <units>micromol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82.0" spread="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Antihypertensive Medications per Patient</title>
          <units>Antihypertensive Medications per Patient</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.8" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Antihypertensive Medications</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Subjects on greater than or equal to 5 medications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects on 4 medications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects on 3 medications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects on 2 medications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Systolic and Diastolic Blood Pressure at Six (6) Months as Measured by Office-based Blood Pressure Assessment</title>
        <description>Change in systolic and diastolic blood pressure at six (6) months as measured by office-based blood pressure assessment following therapeutic renal denervation compared to baseline. Office blood pressure will be measured using a validated electronic device according to a standardized procedure. .</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>Analysis was intention to treat; all participants in the study were to undergo clinical follow up to provide the information needed for this endpoint; 3 participants were not evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>All subjects who meet the inclusion criteria and are enrolled in this trial will be treated with the Vessix Renal Denervation System.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic and Diastolic Blood Pressure at Six (6) Months as Measured by Office-based Blood Pressure Assessment</title>
          <description>Change in systolic and diastolic blood pressure at six (6) months as measured by office-based blood pressure assessment following therapeutic renal denervation compared to baseline. Office blood pressure will be measured using a validated electronic device according to a standardized procedure. .</description>
          <population>Analysis was intention to treat; all participants in the study were to undergo clinical follow up to provide the information needed for this endpoint; 3 participants were not evaluable.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.5" spread="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.3" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absence of Flow Limiting Stenosis in the Renal Artery</title>
        <description>Absence of flow limiting stenosis in the renal artery at six (6) months follow up time point as measured by renal duplex ultrasound</description>
        <time_frame>6 months</time_frame>
        <population>Analysis was intention to treat; all participants in the study were to undergo clinical follow up to provide the information needed for this endpoint; 3 participants were not evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>All subjects who meet the inclusion criteria and are enrolled in this trial will be treated with the Vessix Renal Denervation System.</description>
          </group>
        </group_list>
        <measure>
          <title>Absence of Flow Limiting Stenosis in the Renal Artery</title>
          <description>Absence of flow limiting stenosis in the renal artery at six (6) months follow up time point as measured by renal duplex ultrasound</description>
          <population>Analysis was intention to treat; all participants in the study were to undergo clinical follow up to provide the information needed for this endpoint; 3 participants were not evaluable.</population>
          <units>participants w/o flow limiting stenosis</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Systolic and Diastolic Blood Pressure at Six (6) Months as Measured by 24-hour Ambulatory Blood Pressure</title>
        <description>Change in systolic and diastolic blood pressure at six (6) months as measured by 24-hour ambulatory blood pressure monitoring (ABPM) following therapeutic renal denervation compared to baseline using a validated ABPM device.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>Analysis was intention to treat; all participants in the study were to undergo clinical follow up to provide the information needed for this endpoint; 76 participants were not evaluable at either the baseline or 6 month assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>All subjects who meet the inclusion criteria and are enrolled in this trial will be treated with the Vessix Renal Denervation System.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic and Diastolic Blood Pressure at Six (6) Months as Measured by 24-hour Ambulatory Blood Pressure</title>
          <description>Change in systolic and diastolic blood pressure at six (6) months as measured by 24-hour ambulatory blood pressure monitoring (ABPM) following therapeutic renal denervation compared to baseline using a validated ABPM device.</description>
          <population>Analysis was intention to treat; all participants in the study were to undergo clinical follow up to provide the information needed for this endpoint; 76 participants were not evaluable at either the baseline or 6 month assessment.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.0" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.7" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Artery Dissection or Perforation During the Procedure That Requires Stenting or Surgery</title>
        <time_frame>Duration of the procedure (average of 65 minutes)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>All subjects who meet the inclusion criteria and are enrolled in this trial will be treated with the Vessix Renal Denervation System.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Artery Dissection or Perforation During the Procedure That Requires Stenting or Surgery</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Artery Infarction or Embolus</title>
        <time_frame>Duration of the procedure (average of 65 minutes)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>All subjects who meet the inclusion criteria and are enrolled in this trial will be treated with the Vessix Renal Denervation System.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Artery Infarction or Embolus</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cerebrovascular Accident (CVA) at Time of Procedure</title>
        <time_frame>Duration of the procedure (average of 65 minutes)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>All subjects who meet the inclusion criteria and are enrolled in this trial will be treated with the Vessix Renal Denervation System.</description>
          </group>
        </group_list>
        <measure>
          <title>Cerebrovascular Accident (CVA) at Time of Procedure</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Infarction at Time of Procedure</title>
        <time_frame>Duration of the procedure (average of 65 minutes)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>All subjects who meet the inclusion criteria and are enrolled in this trial will be treated with the Vessix Renal Denervation System.</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Infarction at Time of Procedure</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sudden Cardiac Death at Time of Procedure</title>
        <time_frame>Duration of the procedure (average of 65 minutes)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>All subjects who meet the inclusion criteria and are enrolled in this trial will be treated with the Vessix Renal Denervation System.</description>
          </group>
        </group_list>
        <measure>
          <title>Sudden Cardiac Death at Time of Procedure</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Angiographically-documented Renal Stenosis Requiring an Intervention</title>
        <time_frame>2 Years</time_frame>
        <population>Analysis was intention to treat; all participants in the study were to undergo clinical follow up to provide the information needed for this endpoint; 22 participants were not evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>All subjects who meet the inclusion criteria and are enrolled in this trial will be treated with the Vessix Renal Denervation System.</description>
          </group>
        </group_list>
        <measure>
          <title>Angiographically-documented Renal Stenosis Requiring an Intervention</title>
          <population>Analysis was intention to treat; all participants in the study were to undergo clinical follow up to provide the information needed for this endpoint; 22 participants were not evaluable.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chronic Symptomatic Orthostatic Hypotension</title>
        <time_frame>2 Years</time_frame>
        <population>Analysis was intention to treat; all participants in the study were to undergo clinical follow up to provide the information needed for this endpoint; 22 participants were not evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>All subjects who meet the inclusion criteria and are enrolled in this trial will be treated with the Vessix Renal Denervation System.</description>
          </group>
        </group_list>
        <measure>
          <title>Chronic Symptomatic Orthostatic Hypotension</title>
          <population>Analysis was intention to treat; all participants in the study were to undergo clinical follow up to provide the information needed for this endpoint; 22 participants were not evaluable.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypertensive Emergency Necessitating Hospital Admission (Unrelated to Medication and/or Non-compliance)</title>
        <time_frame>2 Years</time_frame>
        <population>Analysis was intention to treat; all participants in the study were to undergo clinical follow up to provide the information needed for this endpoint; 22 participants were not evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>All subjects who meet the inclusion criteria and are enrolled in this trial will be treated with the Vessix Renal Denervation System.</description>
          </group>
        </group_list>
        <measure>
          <title>Hypertensive Emergency Necessitating Hospital Admission (Unrelated to Medication and/or Non-compliance)</title>
          <population>Analysis was intention to treat; all participants in the study were to undergo clinical follow up to provide the information needed for this endpoint; 22 participants were not evaluable.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduction in Estimated Glomerular Filtration Rate (eGFR) &gt;25%</title>
        <time_frame>2 Years</time_frame>
        <population>Analysis was intention to treat; all participants in the study were to undergo clinical follow up to provide the information needed for this endpoint; 25 participants were not evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>All subjects who meet the inclusion criteria and are enrolled in this trial will be treated with the Vessix Renal Denervation System.</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction in Estimated Glomerular Filtration Rate (eGFR) &gt;25%</title>
          <population>Analysis was intention to treat; all participants in the study were to undergo clinical follow up to provide the information needed for this endpoint; 25 participants were not evaluable.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collect through the 2 year follow up visit.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Renal Denervation</title>
          <description>All subjects who meet the inclusion criteria and are enrolled in this trial will be treated with the Vessix Renal Denervation System.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Other Cardiac - Chest Pain/Angina</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Other Cardiac - Fibrillation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Other Cardiac - Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Other - Gastrointestinal/Rectal</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other Neurological</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Other - Thoracic/Abdominal Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Other - Hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Other - Deconditioning post medical illness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Other - Dementia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Other - Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Other - Overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Other Infectious/Inflammatory</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Other - Inflammation/Infection</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Other - Diabetes</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Other - Skeletal/Connective Tissue</sub_title>
                <counts group_id="E1" events="19" subjects_affected="13" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Other - Suicide Ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Other - Hypertension</sub_title>
                <counts group_id="E1" events="21" subjects_affected="13" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Unanticipated Adverse Events - Prolapsis Uteri</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Other - Priapismus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Other - Prostate Carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Other Pulmonary</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Other - Sleep Apnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Access Site Infection</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Clot or Thrombus Formation</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Other Vascular - Stenosis</sub_title>
                <description>Device Related/Procedure Related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Pseudoaneurysm</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Other - Flank Pain</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Other - Digestive (vomiting)</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Other - Hypertensive Crisis</sub_title>
                <description>Device Related/Procedure Related</description>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Other Cardiac - Hypertensive episode</sub_title>
                <description>Device Related</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Acute Occlusion/Vessel Closure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Stent Required</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Other - Elective Surgery</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Other Vascular - Carotid Stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Other Renal - Renal Calcification</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Other - Limb oedema/ Ulceration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Other - Coronary Sub-Occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Anaesthesia Related - Nausea/Vomiting</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Potentially Related to Device and/or Procedure</description>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>Potentially Related to Device and/or Procedure</description>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Reduced Kidney Function</sub_title>
                <description>Device Related</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Access Site Complications</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" events="22" subjects_affected="20" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <description>Procedure Related</description>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Angela Schutt, Clinical Trial Manager</name_or_title>
      <organization>Boston Scientific</organization>
      <phone>763-494-2166</phone>
      <email>angela.schutt@bsci.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

